Renhe Pharmacy Co (000650.SZ) Stock Price

Renhe Pharmacy Co Price

SZSE·CLOSED
4.93
​
Market closed

Revenue has compounded at 29.8% per year over the past 19 years to 3.54 B CNY. Earnings per share have grown at 3.8% per year over the last 19 years. Renhe Pharmacy Co's net margin stands at 11.1%, down from 13.5% several years earlier. Renhe Pharmacy Co currently offers a dividend yield of about 3.04%. The payout ratio is around 53% of earnings. The dividend has grown at 5.1% per year over the past 15 years.

Renhe Pharmacy Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renhe Pharmacy Co business model & stock analysis

Renhe Pharmacy Co., Ltd. generates revenue through the manufacturing and distribution of pharmaceutical products including capsules, granules, tablets, powder, injections, suppositories, and ointment. The company operates in the domestic market, focusing on medical industrial manufacturing and medical merchandising. Its primary customers are domestic healthcare providers and retail outlets purchasing health-related products for distribution or direct consumer use. The firm's product portfolio spans various dosage forms essential for medical treatment and patient care. The company's business model relies on both wholesale and retail channels within China, serving the domestic pharmaceutical market. Renhe Pharmacy's manufacturing segment produces a wide range of medication forms, while its merchandising division handles the sale of health-related products. This dual approach allows the company to capture value across the pharmaceutical supply chain from production to consumer. Renhe Pharmacy Co., Ltd. serves the Chinese domestic market exclusively, with its operations centered on medical industrial manufacturing and medical merchandising. The company's revenue streams are derived from the sale of its diverse product range to healthcare institutions, pharmacies, and consumers through its retail network. This integrated approach ensures consistent market presence and customer reach within its geographic focus.

Frequently asked questions about Renhe Pharmacy Co

5 analysts currently rate the Renhe Pharmacy Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Renhe Pharmacy Co to generate revenue of 3.82 B CNY and earnings per share of 0.29 CNY.

Converted at the current exchange rate, the Renhe Pharmacy Co share trades at 0.67 EUR (4.93 CNY).

The Renhe Pharmacy Co share (000650.SZ) is listed on 1 stock exchanges, including: Shenzhen (000650.SZ).

The expected revenue of Renhe Pharmacy Co is 3.82 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Renhe Pharmacy Co is 405.98 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Renhe Pharmacy Co is currently 16.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Renhe Pharmacy Co stock.

The price-to-sales ratio (P/S) of Renhe Pharmacy Co is currently 1.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Renhe Pharmacy Co stock.

The Eulerpool Quality Score for Renhe Pharmacy Co is 4/10.

The ISIN of Renhe Pharmacy Co is CNE000000NF8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Renhe Pharmacy Co is 000650.SZ. The ticker symbol is used to trade Renhe Pharmacy Co shares on the stock exchange.

Fair ValueTerminal
4.93 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
583,375.45 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Dec 10, 1996
ISIN
CNE000000NF8
Cusip
Y4444S107
Market capitalization
6.90 B CNYMid Cap
52-Week Range
PEG
2.68
P/E ratio
P/Ee 2026
17.00
P/Ee 2027
15.41
P/Ee 2028
14.09
P/S
P/Se
1.79
EV/EBIT
9.63
P/B Ratio
1.09
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
6.23 %
Dividend
Dividend yield
3.04 %
Est. Dividend Yield
3.08 %
Payout Ratio
52.81 %
Dividend growth Ø5Y
8.71 %
Dividend payments per year
1
Dividend paid since
9 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
10.00 %
Last updated Nov 18, 2026, 6:30 PM

Renhe Pharmacy Co Peer Group

Renhe Pharmacy Co Ticker

SHZ · 000650.SZ

Renhe Pharmacy Co FIGI

000650:CH · BBG000P6CL08000650:CS · BBG000P6CLY1000650:C2 · BBG00F136DF7

All fundamentals and in-depth analysis of Renhe Pharmacy Co

Our stock analysis for Renhe Pharmacy Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Renhe Pharmacy Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.